Nrf-2-SLC7A11-GSH pathway

Overview

The Nrf-2-SLC7A11-GSH pathway is a redox-regulatory cascade in which the transcription factor Nrf2 drives expression of SLC7A11 (xCT), the light chain of the cystine/glutamate antiporter system xc−, which imports cystine in exchange for exporting glutamate and so supplies the cysteine that limits glutathione (GSH) synthesis. Under basal conditions Nrf2 is bound by Kelch-like ECH-associated protein 1 (KEAP1) and continuously degraded; oxidative or electrophilic stress modifies reactive cysteines on KEAP1, releasing Nrf2 to accumulate in the nucleus and induce cytoprotective genes including SLC7A11 and heme oxygenase 1. The resulting GSH sustains glutathione peroxidase 4 (GPX4), which reduces lipid hydroperoxides and limits reactive oxygen species accumulation. The axis therefore couples antioxidant transcription, cystine transport and thiol metabolism into one defense against oxidative stress — with a cost, since the obligatory glutamate export can deplete extracellular glutamate balance in tissues such as brain.

Because GPX4 depends on GSH, the cascade governs ferroptosis, the iron-dependent death driven by lipid peroxidation and promoted by acyl-CoA synthetase long-chain family member 4 (ACSL4) and by NCOA4-mediated ferritinophagy. Blocking system xc− — with erastin or with sulfasalazine — starves the cell of cysteine and kills it ferroptotically, while activating the axis reinforces resistance.

That duality defines its pharmacology. Nrf2 activators such as omaveloxolone and natural products including wedelolactone, carvacrol and 10-shogaol are studied for protection in sepsis-induced liver injury, doxorubicin cardiotoxicity and neuromuscular disease such as spinal muscular atrophy. In oncology the same axis is a liability: tumors with KEAP1 loss or NRF2 gain-of-function mutations, common in non-small cell lung cancer, run the pathway constitutively and resist anticancer treatments including cisplatin, oxaliplatin and the HER2-directed antibody trastuzumab. Elevated tumor GSH is exploited in turn as a chemical trigger for redox-responsive prodrugs, nanocarriers and combined photothermal or sonodynamic platforms.

Recent Publications Summary

Recent studies have continued to position the Nrf-2-SLC7A11-GSH pathway as a central regulator of redox balance, ferroptosis, and therapy response across diverse disease models. In cancer, this pathway was directly implicated in a self-propelled triptolide prodrug designed to overcome trastuzumab resistance, where acid-triggered release of triptolide induced apoptosis and ferroptosis through the Nrf-2-SLC7A11-GSH pathway and promoted membrane lipid peroxidation 41789437Mar. In osteoarthritis, engineered mesenchymal stem cell exosomes carrying miR-142a-3p were reported to suppress ferroptosis and reactive oxygen species by targeting the GSK3β/Nrf2/SLC7A11 axis, improving protection against cartilage matrix degradation 41637927Feb. Related ferroptosis-focused studies also showed that paclitaxel plus sunitinib downregulated SLC7A11 alongside GPX4 and FTH1 to drive ferroptosis in lung cancer, reinforcing the importance of SLC7A11 in therapeutic sensitivity 41955701Apr.

Several publications linked pharmacologic or natural-product activation of Nrf2 to increased antioxidant defense through SLC7A11 and glutathione-related signaling. Omaveloxolone increased NRF2 target proteins including xCT/SLC7A11 in spinal muscular atrophy fibroblasts and improved cell viability 42301137Jun. 10-Shogaol was described as a novel Nrf2 activator that inhibited Keap1-mediated ubiquitination and proteasome degradation, induced antioxidant gene expression, and suppressed inflammatory signaling in viral infection models 42270434Jun. carvacrol was also associated with cardioprotection in doxorubicin-induced injury through Nrf2/Keap1-related signaling, with the study evaluating Nrf2, Keap1, and extracellular vesicle-associated MALAT1 42259137Jun. In diabetic diarrhea, acupuncture combined with Warm Kidney and Spleen Granules activated Nrf2/HO-1 signaling and improved oxidative stress and inflammatory markers, including GSH-related readouts 42105678May. liraglutide likewise alleviated postoperative cognitive impairment in aged mice via GLP-1R/NRF2 signaling, reducing ROS and NLRP3 inflammasome activation 42102962May.

Other reports used GSH responsiveness as a therapeutic trigger or readout in nanomedicine and drug delivery systems. A COF-mediated platform stabilized a disulfide-linked prodrug that was activated by GSH in the tumor microenvironment to support combined chemo-sonodynamic therapy 42329078Jun. A GSH-responsive albumin-based nanosystem for lung cancer released its payload under intracellular reductive conditions to restore photosensitizer activity and enhance cerenkov-induced photodynamic therapy 41795323Mar. In breast cancer, a copper-doped Prussian blue hydrogel promoted GSH depletion and oxidative stress amplification during multimodal therapy 42177922May. In sepsis-induced liver injury, wedelolactone-loaded exosomes improved liver targeting, hepatoprotection, antioxidant function, and ferroptosis suppression 42381381Jul. Together, these studies underscore the pathway’s recurring role as a mechanistic node connecting oxidative stress control, glutathione metabolism, and ferroptosis-based therapeutic strategies across inflammatory, degenerative, and malignant disease settings.

What Changes, What Holds

1. The pathway remains a central ferroptosis and therapy-response node, but now with sharper evidence for pro- and anti-ferroptotic uses
REINFORCES Triptolide-based redox therapy and the miR-142a-3p exosome study both fit the established model that Nrf2-SLC7A11-GSH controls lipid peroxidation and cell survival, while the paclitaxel/sunitinib report further supports SLC7A11 as a determinant of treatment sensitivity 41789437Mar41637927Feb. What changes is not the mechanism but the range of disease settings in which it is being operationalized, including cartilage protection and trastuzumab resistance.

2. Nrf2 activation still looks protective, but the new work broadens the pathway’s translational reach beyond the diseases already named
REINFORCES Omaveloxolone, 10-shogaol, carvacrol, acupuncture-based treatment, and liraglutide all reinforce the baseline claim that Nrf2 activation can raise antioxidant defenses and reduce oxidative injury through downstream redox programs, including SLC7A11/GSH-linked readouts 42301137Jun42270434Jun. The main update is practical rather than conceptual: these reports extend the same axis into spinal muscular atrophy, viral inflammation, cardiotoxicity, diabetic diarrhea, and postoperative cognitive impairment without challenging the core mechanism.

3. GSH responsiveness is becoming a design principle for therapy, not just a biomarker of redox state
NEW DIRECTION COF-stabilized prodrugs, GSH-responsive albumin nanocarriers, and GSH-depleting hydrogels show that the baseline’s tumor-GSH exploitation is expanding into more deliberate control of payload release and redox amplification 42329078Jun41795323Mar. Wedelolactone exosomes in sepsis-induced liver injury also point to a broader therapeutic logic, but this does not overturn the established pathway; it adds new delivery and activation strategies that use GSH as a trigger or target.

Overview update candidates: GSH-responsive drug delivery and GSH-depleting multimodal therapy as established therapeutic strategies; broader translational use of Nrf2 activation in additional disease models.